Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series

  1. Ashkan Mowla
  2. Banafsheh Shakibajahromi
  3. Shima Shahjouei
  4. Afshin Borhani-Haghighi
  5. Nasrin Rahimian
  6. Humain Baharvahdat
  7. Soheil Naderi
  8. Fariborz Khorvash
  9. Davar Altafi
  10. Seyed Amir Ebrahimzadeh
  11. Ghasem Farahmand
  12. Alaleh Vaghefi Far
  13. Vijay K. Sharma
  14. Saeideh Aghayari Sheikh Neshin
  15. Georgios Tsivgoulis
  16. Ramin Zand

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jns.2020.117183
  2. ScreenIT

    SciScore for 10.1101/2020.09.12.20186106: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study protocol was designed by the investigators at the Neuroscience Institute of Geisinger Health System, Pennsylvania, USA, and received approval by the Institutional Review Board (IRB) of Geisinger Health System and other participating institutions when it was required. 2.3.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    We applied SPSS software for statistical analysis.(24)
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    To the best of our knowledge, our study is the largest case series to date on patients with SARS-CoV-2 infection who developed CVST; however, it has several limitations. It has a small size; however, given it is the largest case series on this topic up to the present time, it can still provide valuable information about such patients compared with the non-SARS-CoV-2 infected patients. Additionally, there might be a degree of selection bias. Since our cases were received from particular tertiary centers that were invited to participate, and the majority of the patients were recruited from one country, they might not properly represent the population of COVID-19 patients who present with neurological symptoms; nevertheless, we selected the control cohort from the same country. Furthermore, there were several missing data in a couple of our patients, and given it is a multicenter study, laboratory data were not unified in all centers. In addition, the lack of a complete inherited thrombophilia assessment in some cases could be a source of bias in the interpretation of our analysis on identified CVST risk factors.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.09.12.20186106v1 on medRxiv